Pharma BD Deal Intelligence
Qilu Pharmaceutical Group Co., Ltd. / Insilico Medicine Inc.
2026 · Licensing/Option · $120M · Complete
Insilico Medicine and Qilu Pharmaceutical Group, together with its subsidiary Shanghai Qilu Pharmaceutical Research Center, entered a drug-development collaboration under which Insilico designs and optimizes novel small-molecule inhibitors against undisclosed cardiometabolic targets using its Pharma.AI platform and Qilu takes responsibility for subsequent development and commercialization. Total contract value is approximately US$120 million in development and commercialization milestones plus single-digit royalties on net sales; the upfront was not disclosed. The deal deepens a relationship that started in 2021 with Qilu's use of Insilico's PandaOmics software.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.
Key facts
- Announced Jan 27, 2026
- Deal value $120M
- Deal type Licensing/Option
- Therapeutic area Metabolic, Cardiovascular
- Indications Cardiometabolic disease
- Key assets Small-molecule inhibitor programs against undisclosed cardiometabolic targets, designed and optimized on Insilico's Pharma.AI platform
- Mechanism Generative-AI-driven design and optimization of novel small-molecule inhibitors against undisclosed cardiometabolic targets
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2026 deals · Metabolic deals